文献速递头颈部肿瘤放疗

在三种人乳头瘤病毒(HPV)阴性和三种HPV阳性头颈部鳞状细胞癌(HNSCC)异种移植瘤模型中比较单纯放疗与标准化放化疗的临床前试验

Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
PubMed 文献 · Radiother Oncol · 2023-02-20

该临床前试验在三种HPV阴性和三种HPV阳性HNSCC裸鼠异种移植瘤中比较分次放疗与联合顺铂的放化疗的疗效。三种HPV阴性模型中有一种、三种HPV阳性模型中有两种显示放化疗较单纯放疗显著提高局部肿瘤控制。HPV阳性模型汇总分析显示放化疗较单纯放疗有统计学显著且实质性的获益,增强比为1.34。

要点

  • 三种HPV阴性模型中有一种、三种HPV阳性模型中有两种显示放化疗较单纯放疗显著提高局部肿瘤控制。
  • HPV阳性模型汇总分析显示放化疗较单纯放疗有统计学显著且实质性的获益,增强比为1.34。
  • 放化疗对局部控制的影响在HPV阴性和HPV阳性肿瘤中均存在异质性,作者认为需要预测性生物标志物。

核心结论

  • 放化疗对局部控制的影响在HPV阴性和HPV阳性肿瘤中均存在异质性,作者认为需要预测性生物标志物。
  • 放化疗在全部HPV阳性肿瘤汇总组中实质性提高局部肿瘤控制,而在HPV阴性肿瘤中未发现这一效果。
  • 作者认为本临床前试验不支持在HPV阳性HNSCC的治疗降阶策略中省略化疗。

研究设计与样本

  • 临床前试验,在裸鼠中使用三种HPV阴性和三种HPV阳性HNSCC异种移植瘤,随机分配至单纯放疗或联合每周顺铂的放化疗。
  • 为评估肿瘤生长时间,给予20 Gy放疗(±顺铂),分10次、2周完成。
  • 为生成局部肿瘤控制的剂量-反应曲线,给予30次、6周的不同剂量水平放疗,单用或联合顺铂(放化疗)。

主要发现

  • 三种HPV阴性模型中有一种、三种HPV阳性模型中有两种显示放化疗较单纯放疗显著提高局部肿瘤控制。
  • HPV阳性模型汇总分析显示放化疗较单纯放疗有统计学显著且实质性的获益,增强比为1.34。
  • 在不同HPV阳性HNSCC之间也观察到对放疗和放化疗反应的异质性,但总体而言HPV阳性模型比HPV阴性模型对放疗和放化疗更敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform a preclinical trial comparing the efficacy of fractionated radiotherapy versus radiochemotherapy with cisplatin in HPV-positive and negative human head and neck squamous cell carcinoma (HNSCC) xenografts. MATERIAL AND METHODS: Three HPV-negative and three HPV-positive HNSCC xenografts in nude mice were randomized to radiotherapy (RT) alone or to radiochemotherapy (RCT) with weekly cisplatin. To evaluate tumour growth time, 20 Gy radiotherapy (±cisplatin) were administered in 10 fractions over 2 weeks. Dose-response curves for local tumour control were generated for RT with 30 fractions over 6 weeks to different dose levels given alone or combined with cisplatin (RCT). RESULTS: One of three investigated HPV-negative and two out of three HPV-positive tumour models showed a significant increase in local tumour control after RCT compared to RT alone. Pooled analysis of the HPV-positive tumour models showed a statistically significant and substantial benefit of RCT versus RT alone, with an enhancement ratio of 1.34. Although heterogeneity in response to both RT and RCT was also observed between the different HPV-positive HNSCC, these overall were more RT and RCT sensitive than HPV-negative models. CONCLUSION: The impact of adding chemotherapy to fractionated radiotherapy on local control was heterogenous, both in HPV-negative and in HPV-positive tumours, calling for predictive biomarkers. RCT substantially increased local tumour control in the pooled group of all HPV-positive tumours whereas this was not found in HPV-negative tumours. Omission of chemotherapy in HPV-positive HNSCC as part of a treatment de-escalation strategy is not supported by this preclinical trial.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Valentini C, Ebert N, Koi L, et al. Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models. Radiother Oncol. 2023. PMID: 36813172. doi:10.1016/j.radonc.2023.109546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。